Filing Flows › PAVmed (PAVM) › Q3 2025
PAVmed (PAVM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
PAVmed (PAVM) reported revenue of $5K for the third quarter 2025 (Q3 2025), -100% from a year earlier and -17% from the quarter before.
PAVmed, Q3 2025: revenue $5K (-100% year over year), net loss $6.0M, operating cash flow −$896K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | -17% | -100% |
| Operating profit | −$4.8M | — | — |
| Net earnings | −$6.0M | — | — |
| Operating cash flow | −$896K | — | — |
What changed
Revenue was $5K in Q3 2025, down 100% year over year and down 17% from the previous quarter.
Operating costs exceeded revenue by $4.8M, an operating margin of -96880.0%. Total costs fell 61% while revenue fell 100%. The quarter ended with a net loss of $6.0M, narrower than the previous quarter's $12.3M loss. Minority interests bore $628K of it: to shareholders the quarter was a loss of $5.4M.
Operating cash flow was −$896K. Non-cash charges added back $22K of depreciation and amortization and $383K of share-based compensation. Working capital and other items added $4.7M. Capital expenditures of $3K exceeded it, leaving free cash flow of −$899K.
Questions
What was PAVmed's revenue in the third quarter 2025?
PAVmed (PAVM) reported revenue of $5K for the third quarter 2025 (Q3 2025), -100% from a year earlier and -17% from the quarter before.
Source: PAVmed 10-Q on SEC EDGAR.